CoChat

mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant

Open access
Parry, Helen, Tut, Gokhan, Bruton, Rachel, Faustini, Sian, Stephens, Christine, Saunders, Philip, Bentley, Christopher, Hilyard, Katherine, Brown, Kevin, Amirthalingam, Gayatri, Charlton, Sue, Leung, Stephanie, Chiplin, Emily, Coombes, Naomi S, Bewley, Kevin R, Penn, Elizabeth J, Rowe, Cathy, Otter, Ashley, Watts, Rosie, D'Arcangelo, Silvia, Hallis, Bassam, Makin, Andrew, Richter, Alex, Zuo, Jianmin, Moss, Paul · 2021 · eLife
Cited by 36

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have received priority consideration for COVID-19 vaccination. However, vaccine responses are often suboptimal in this age group and few people over the age of 80 years were included in vaccine registration trials. We determined the serological and cellular response to spike protein in 100 people aged 80–96 years at 2 weeks after the second vaccination with the Pfizer BNT162b2 mRNA vaccine. Antibody responses were seen in every donor with high titers in 98%. Spike-specific cellular immune responses were detectable in only 63% and correlated with humoral response. Previous SARS-CoV-2 infection substantially increased antibody responses after one vaccine and antibody and cellular responses remained 28-fold and 3-fold higher, respectively, after dual vaccination. Post-vaccine sera mediated strong neutralization of live Victoria infection and although neutralization titers were reduced 14-fold against the P.1 variant first discovered in Brazil they remained largely effective. These data demonstrate that the mRNA vaccine platform delivers strong humoral immunity in people up to 96 years of age and retains broad efficacy against the P.1 variant of concern.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.69375

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 10

  1. Chen, 2021, Resistance of SARS-COV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies, Nature Medicine, 27, 717, 10.1038/s41591-021-01294-w · DOI · Paper page
  2. Cook, 2020, Validation of a Combined Elisa to Detect Igg, Iga and IGM Antibody Responses to SARS-COV-2 in Mild or Moderate Non-Hospitalised Patients, 10.1101/2020.11.30.20229732 · doi:10.1101/2020.11.30.20229732
  3. Egorov, 2018, The changing landscape of naive T cell receptor repertoire with human aging, Frontiers in Immunology, 9, 10.3389/fimmu.2018.01618 · DOI · Paper page
  4. Krutikov, 2021, Incidence of SARS-CoV-2 Infection According to Baseline Antibody Status in Staff and Residents of 100 Long Term Care Facilities (VIVALDI Study, 10.1101/2021.03.08.21253110 · DOI
  5. Levi, 2021, A Cautionary Note on Recall Vaccination in Ex-COVID-19 Subjects, 10.1101/2021.02.01.21250923 · DOI
  6. Manisty, 2021, Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection, EBioMedicine, 65, 10.1016/j.ebiom.2021.103259 · DOI
  7. Morley, 2020, Sensitive Detection of SARS-CoV-2–Specific Antibodies in Dried Blood Spot Samples, Emerging Infectious Disease Journal, 26, 10.3201/eid2612.203309 · DOI
  8. Pietrobon, 2020, I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People, Frontiers in Immunology, 11, 10.3389/fimmu.2020.579220 · DOI · Paper page
  9. Salvagno, 2021, Anti-sars-cov-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mrna bnt162b2 vaccination, Diagnostics, 11, 10.3390/diagnostics11050832 · DOI
  10. Zuo, 2021, Author Correction: Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection, Nature Immunology, 22, 10.1038/s41590-021-00957-7 · doi:10.1038/s41590-021-00957-7

Cited by

See all 36

Metadata

Authors
Parry, H., Tut, G., Bruton, R., Faustini, S., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K., Amirthalingam, G., Charlton, S., Leung, S., Chiplin, E., Coombes, N. S., Bewley, K. R., Penn, E. J., Rowe, C., Otter, A., Watts, R., D'Arcangelo, S., Hallis, B., Makin, A., Richter, A., Zuo, J., & Moss, P.
Venue
eLife
Published
2021-09-29
Volume
10
ISSN
2050-084X (ISSN-L)
OpenAlex
W3203293048
Cited by
36
References
12
FWCI
2.52
Type
journal article
Language
en
Open access
gold
Funders
  • National Core Studies (Immunity programme)
  • UK Coronavirus Immunology Consortium (UKRI/DHSC)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. https://app.cochat.ai/papers/10.7554/elife.69375
The paper
Parry, H., Tut, G., Bruton, R., Faustini, S., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K., Amirthalingam, G., Charlton, S., Leung, S., Chiplin, E., Coombes, N. S., Bewley, K. R., Penn, E. J., Rowe, C., Otter, A., Watts, R., . . . Moss, P. (2021). mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. eLife. https://doi.org/10.7554/elife.69375

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.